Repligen Corporation $RGEN Shares Bought by Retirement Systems of Alabama

Retirement Systems of Alabama boosted its position in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) by 6.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 58,210 shares of the biotechnology company’s stock after acquiring an additional 3,368 shares during the quarter. Retirement Systems of Alabama owned 0.09% of Repligen worth $11,190,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of RGEN. North Dakota State Investment Board boosted its position in Repligen by 4.1% in the third quarter. North Dakota State Investment Board now owns 1,630 shares of the biotechnology company’s stock worth $313,000 after purchasing an additional 64 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Repligen by 35.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 374 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 98 shares during the period. ABS Investment Management LLC purchased a new stake in shares of Repligen during the 2nd quarter valued at about $191,016,000. State of Alaska Department of Revenue increased its position in shares of Repligen by 2.9% during the 3rd quarter. State of Alaska Department of Revenue now owns 5,346 shares of the biotechnology company’s stock valued at $1,027,000 after purchasing an additional 150 shares during the last quarter. Finally, Crossmark Global Holdings Inc. increased its position in shares of Repligen by 3.5% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 4,525 shares of the biotechnology company’s stock valued at $870,000 after purchasing an additional 152 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

NASDAQ RGEN opened at $167.79 on Monday. The stock’s 50-day moving average price is $177.15 and its 200-day moving average price is $145.67. The company has a quick ratio of 8.43, a current ratio of 9.88 and a debt-to-equity ratio of 0.27. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $198.87. The company has a market capitalization of $10.73 billion, a P/E ratio of -798.96, a price-to-earnings-growth ratio of 2.88 and a beta of 1.11.

Repligen (NASDAQ:RGEN – Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. The firm had revenue of $209.31 million for the quarter, compared to analysts’ expectations of $206.70 million. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The business’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.46 EPS. On average, equities research analysts predict that Repligen Corporation will post 2.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on RGEN shares. UBS Group reissued a “buy” rating on shares of Repligen in a report on Tuesday, September 29th. JPMorgan Chase & Co. boosted their target price on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Barclays upped their target price on shares of Repligen from $175.00 to $225.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Weiss Ratings downgraded shares of Repligen from a “hold (c)” rating to a “sell (d+)” rating in a research report on Monday, November 2nd. Finally, Wells Fargo & Company lifted their price target on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $178.57.

Get Our Latest Stock Report on RGEN

Repligen Profile

(Free Report)

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.

Further Reading

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.